# EDGAR Filing Document

**Accession Number:** 0001892421
**File Stem:** 0001493152-25-022423
**Filing Date:** 2025-11
**Character Count:** 8605
**Document Hash:** 78a9526eab867607c9411c77a845f27e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-022423.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001493152-25-022423

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bio Green Med Solution, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-80136
- **FILM NUMBER:** 251480153

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20060329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Doris Wong Sing Ee
- **CENTRAL INDEX KEY:** 0001892421

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 10, TOWER 11, AVENUE 5, NO. 8
- **STREET 2:** JALAN KERINCHI, BANGSAR SOUTH
- **CITY:** WILAYAHPERSEKUTUANKUALA LUMPUR
- **STATE:** N8
- **ZIP:** 59200

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Bio Green Med Solution, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**23254L876**

*(CUSIP Number)*

**Datuk Dr. Doris Wong Sing Ee**<br>Level 10, Tower 11, Avenue 5, No. 8<br>Jalan Kerinchi,<br>Kuala Lumpur N8 59200<br>60 (12) 223 7897

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **23254L876** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Doris Wong Sing Ee** | Name of reporting person<br>**Doris Wong Sing Ee** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**N8** | Citizenship or place of organization<br>**N8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1111131.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1111131.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1111131.00** | Aggregate amount beneficially owned by each reporting person<br>**1111131.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**20.58%** | Percent of class represented by amount in Row (11)<br>**20.58%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** As adjusted for 1-for-16 reverse stock split on May 12, 2025 and 1-for-15 reverse stock split on July 7, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Bio Green Med Solution, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, N8, 59200

**Item 4. Purpose of Transaction**

Datuk Dr. Doris Wong Sing Ee purchased the shares pursuant to the Securities Purchase Agreement. In connection with the purchase, Datuk Dr. Doris Wong Sing Ee was appointed as Chief Executive Office and as an Executive Director of the Issuer. Subject to ongoing evaluation, except as set forth above, the Reporting Person has no current plans or proposals which relate to or would result in any of the following: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940; (g) Changes in the Issuer's charter, bylaws, or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) Any action similar to any of those enumerated above. See also Item 3.

The shares of common stock were granted on November 12, 2025 to Datuk Dr. Doris Wong Sing Ee under the Issuer's 2018 Equity Incentive Plan for services rendered.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person has the sole power vote or to direct the vote and the sole power to dispose or to direct the disposition of the 1,111,131 shares of common stock (the "Shares") of the Issuer. The percentage of Shares reported to be beneficially owned by the Reporting Person is based on information from the Issuer. Thus, the Reporting Person is deemed to be the beneficial owner of an aggregate 20.58% of the common stock of the Issuer.

**(b)**
The Reporting Person has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the 1,111,131 shares of common stock (the "Shares") of the Issuer. The percentage of Shares reported to be beneficially owned by the Reporting Person is based on information from the Issuer. Thus, the Reporting Person is deemed to be the beneficial owner of an aggregate 20.58% of the common stock of the Issuer.

**(c)**
Except as described in Item 4, during the past 60 days, the Reporting Person has not effected any transactions with respect to the shares of common stock of the Issuer.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Reference is made to the transaction stated in Item 3 above.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Doris Wong Sing Ee

**Signature:** /s/ Datuk Dr. Doris Wong Sing Ee

**Name/Title:** Chief Executive Officer and Executive Director

**Date:** 11/13/2025